Bavachalcone targets transferrin receptor and sensitizes gemcitabine to affect bladder cancer progression
{{output}}
Gemcitabine resistance drives bladder cancer recurrence and progression. Using high-throughput drug screening in bladder cancer cells, we identified Bavachalcone (Bava) as a potent gemcitabine sensitizer. Mechanistically, Bava simultaneously targets transferri... ...
